Results 231 to 240 of about 509,312 (356)

Affibody-based optical imaging probe for noninvasive detection of liver fibrosis. [PDF]

Theranostics
Kashfi Sadabad R, Marinec PS, Lechuga L, Thompson R, Cheng R, Saigal A, Vinales I, Martinez S, Solis AE, Newman EMT, Goncin U, Novotny C, Miller C, Chin CL.   +13 more
europepmc   +1 more source

LMO7 Suppresses Tumor‐Associated Macrophage Phagocytosis of Tumor Cells Through Degradation of LRP1

Advanced Science, EarlyView.
LMO7 in tumor‐associated macrophages suppresses phagocytosis of tumor cells and limits cytotoxic T lymphocytes infiltration, fostering tumor progression. Mechanistically, LMO7 mediates the ubiquitination and degradation of the phagocytic receptor LRP1, impairing its ability to engulf tumor cells and driving macrophages toward an antitumor phenotype ...
Mengkai Li, Tao Wang, Yuwen Zhong, Zhiming Wang, Wei Li, Zejian Wang, Xinyi Yang, Yu Qiao, Jianfeng Xiang, Wei Gu, Zishu Wang, Lei Sun, Feng Qian   +12 more
wiley   +1 more source

Liver Fibrosis and the Risks of Impaired Cognition and Dementia: Mechanisms, Evidence, and Clinical Implications. [PDF]

Med Sci (Basel)
Jamalinia M, Weiskirchen R, Lonardo A.
europepmc   +1 more source

4CPS-090 Health outcomes using direct-acting antiviral drugs for the treatment of patients with hepatitis C virus and F0–F1 liver fibrosis stage [PDF]

, 2019
M Martín López, B Hernández Muniesa, A Ontañón Nasarre, A. Alonso, Núbia Muñóz, M.G. Gil   +5 more
openalex   +1 more source

Nuclear Factor I‐B Delays Liver Fibrosis by Inhibiting Chemokine Ligand 5 Transcription

Advanced Science, EarlyView.
This study identifies the transcription factor Nuclear Factor I‐B (NFIB) as a key suppressor of liver fibrosis. NFIB expression declines during hepatic stellate cell activation, and its overexpression reduces fibrosis in mice models. The mechanism involves NFIB directly repressing chemokine C─C motif ligand 5 (CCL5), thereby alleviating oxidative ...
Qianqian Chen, Fajuan Rui, Zhiwen Fan, Hongju Yang, Nan Geng, Chenqi Lu, Wenjing Ni, Yue Huan, Junping Shi, Chao Wu, Shengxia Yin, Wei An, Xia Lu, Qianwen Zhao, Jie Li   +14 more
wiley   +1 more source

Liver Fibrosis as a Predictor of Cardiovascular Risk in Patients with Severe Obesity. [PDF]

J Clin Med
Saidi AN, Theel WB, de Jong VD, van Mil SR, van der Lely AJ, Grobbee DE, Apers J, Beek EVZ, Castro Cabezas M.   +8 more
europepmc   +1 more source

GP285 The effect of modulator therapy on liver function in patients with cystic fibrosis-related liver disease (CFLD) [PDF]

, 2019
Sharon Dempsey, John Travers, Gerardine Leer, Geraldine Connell, Shona Quinn, Peter Greally, B. Elnazir   +6 more
openalex   +1 more source

Promoting Autophagy Mitigates Stress‐Induced Remodeling in Patient iPSC‐CMs with the Phospholamban R9C Mutation

Advanced Science, EarlyView.
The Phospholamban (PLN) R9C mutation reduces SERCA2a binding, increasing calcium recycling and baseline contractility. However, the excess of free PLN promotes pentamer formation, limiting phosphorylation and blunting β‐adrenergic signaling. Under cardiac stress, enhanced functional demands overwhelm proteostasis in PLN R9C cells, leading to misfolded ...
Qi Yu, Yawei Shen, Robert J. Barndt, Karim Sallam, Ying Tang, Cameron E. Brown, Xiao Li, Stephen Y. Chan, Joseph C. Wu, Qing Liu, Haodi Wu   +10 more
wiley   +1 more source

LivSCP: Improving Liver Fibrosis Classification Through Supervised Contrastive Pretraining. [PDF]

Diagnostics (Basel)
Dubey Y, Bhongade A, Fulzele P.
europepmc   +1 more source

[Liver fibrosis].

Revista de gastroenterologia de Mexico, 1997
S, Taba Shiwa, N, Garibay-Nieto, P, Angulo-Hernández, F, Vargas-Vorackova, D, Kershenobich   +4 more
openaire   +1 more source